Explore recent issues of Contract Pharma covering key industry trends.
Read the full digital version of our magazine online.
Behind every facility expansion, technology investment, and quality milestone in the CDMO sector is a leadership team making deliberate choices about where to focus, how to grow, and when to take calculated risks.
Stay informed! Subscribe to Contract Pharma for industry news and analysis.
Get the latest updates and breaking news from the pharmaceutical and biopharmaceutical industry.
Discover the newest partnerships and collaborations within the pharma sector.
Keep track of key executive moves and promotions in the pharma and biopharma industry.
Updates on the latest clinical trials and regulatory filings.
Stay informed with the latest financial reports and updates in the pharma industry.
A video roundup of the week’s top industry news stories.
Expert Q&A sessions addressing crucial topics in the pharmaceutical and biopharmaceutical world.
In-depth articles and features covering critical industry developments.
Access exclusive industry insights, interviews, and in-depth analysis.
Insights and analysis from industry experts on current pharma issues.
A one-on-one video interview between our editorial teams and industry leaders.
Listen to expert discussions and interviews in pharma and biopharma.
Contract Pharma Stream offers a centralized destination where users can watch expert-led sessions anytime, anywhere
A detailed look at the leading US players in the global pharmaceutical and BioPharmaceutical industry.
Browse companies involved in pharmaceutical manufacturing and services.
Comprehensive company profiles featuring overviews, key statistics, services, and contact details.
A comprehensive glossary of terms used in the pharmaceutical and biopharmaceutical industry.
Watch in-depth videos featuring industry insights and developments.
Download in-depth eBooks covering various aspects of the pharma industry.
Access detailed whitepapers offering analysis on industry topics.
View and download brochures from companies in the pharmaceutical sector.
Explore content sponsored by industry leaders, providing valuable insights.
Stay updated with the latest press releases from pharma and biopharma companies.
Explore top companies showcasing innovative pharma solutions.
Meet the leaders driving innovation and collaboration.
Engage with sessions and panels on pharma’s key trends.
Hear from experts shaping the pharmaceutical industry.
Join online webinars discussing critical industry topics and trends.
A comprehensive calendar of key industry events around the globe.
Live coverage and updates from major pharma and biopharma shows.
Find advertising opportunities to reach your target audience with Contract Pharma.
Review the editorial standards and guidelines for content published on our site.
Understand how Contract Pharma handles your personal data.
View the terms and conditions for using the Contract Pharma website.
What are you searching for?
The sample-to-answer system is based on PCR technology and enables higher throughput than its Bruker predecessor.
April 17, 2026
By: Patrick Lavery
Bruker announced its European launch of the MyGenius PRO molecular diagnostics system, based on polymerase chain reaction (PCR) technology. The announcement, in particular, comes from Bruker Corporation’s Microbiology & Infection Diagnostics division. Importantly, the system’s design focuses on infectious disease diagnostics.
At launch, MyGenius PRO’s In Vitro Diagnostic Regulation (IVDR) menu includes assays for cytomegalovirus and Epstein-Barr virus from blood. An additional assay from urine is BK virus. Menu expansion including HIV, hepatitis B and C, and human herpesvirus 6 is planned throughout 2026.
These assays and sample matrices, Bruker says, help MyGenius PRO support diagnostic testing in immunocompromised patients.
The sample-to-answer (S2A) system is fully automated, allows for continuous loading of samples, consumables, and reagents, and supports random-access operation. Compared with Bruker’s medium-throughput BeGenius system, MyGenius PRO can perform higher throughput. However, like BeGenius, the new system automates the entire workflow, from patient samples to diagnostic results.
Bruker says this enhances laboratory efficiency and supports needs for higher-volume testing. In a recent interview, Dr. Pierangelo Clerici, President of the Italian Association of Clinical Microbiologists, voiced such concerns.
“Timely diagnosis is critical in microbiology and virology,” Clerici said. “Fully automated sample-to-result solutions improve turnaround time and support faster clinical response and effective infection monitoring.”
Clerici added that streamlining lab workflows can help ensure regulatory compliance.
ELITechGroup, a Bruker company, and Hitachi High-Tech Corporation assisted in MyGenius PRO’s development. In fact, Hitachi High-Tech will introduce the system under the moniker Labospect GA-5 in Japan. This version of the system will still use Bruker molecular diagnostic assays, in accordance with Japanese regulations.
Bruker unveiled MyGenius PRO for Europe at the Congress of the European Society of Clinical Microbiology and Infectious Diseases (ECSMID).
Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.
Enter your account email.
A verification code was sent to your email, Enter the 6-digit code sent to your mail.
Didn't get the code? Check your spam folder or resend code
Set a new password for signing in and accessing your data.
Your Password has been Updated !
